Abstract:e19406 Background: Financial toxicity (FT), or the cost-related side effect of cancer therapy, has been linked to poor clinical outcomes, greater symptom burden, and worse quality of life. While the repercussions of FT have been thoroughly explored, the longitudinal patient relationship with FT in the initial course of therapy is unknown. Methods: Patients with stage II – IV lung cancer were recruited in a prospective longitudinal non-interventional study between July 2018 and January 2020. FT was measured via the COST score, a validated questionnaire for benchmarking FT, at a) the time of cancer diagnosis and then later at b) 6-month follow up (6MFU). In this model, a lower COST score indicates increased financial hardship. Completed 6MFU data was compared to corresponding baseline data for each patient. Linear regression analysis was used to compare patient characteristics with baseline COST (COST base ) and 6-month COST (COST 6M ) scores. Results: At the time of analysis, 209 patients were screened and 194 (95.1%) patients agreed to participate and complete the baseline survey. Subsequently, 93 patients completed the 6MFU survey, 32 patients had died, and 7 patients were lost to follow up. The remaining 62 patients have not met the study end point to date. Of the 93 patients that completed the 6MFU and baseline survey, the median age was 65 (range 35-89), 50.5% were male, and 76.3% were Caucasian. Over the first six months of therapy 36.5% overestimated OOP expenses by > $1000 and 22.5% reported a decrease in total monetary savings, but only 4.3% of patients made decisions about health care based on cost of care. FT was present at both time points but was worse at diagnosis than at 6MFU (median COST base 25 [range 1-44] vs. median COST 6M 27 [range 0-44]; p = 0.04). Linear regression correlated risk factors with FT at baseline ( < 1 month monetary savings, employed but on sick leave, and inability to afford basic necessities; all p < 0.001) that were different from risk factors at 6MFU (paying much more than expected OOP and sacrificing spending to meet medical costs; p < 0.001). There was no significant difference between estimated OOP costs at baseline (median $2550 [range $0 - $500,000]) and actual OOP costs (median $2496 [range $0 – 25,900]; p = 0.25). Conclusions: FT toxicity is pervasive at both diagnosis and at 6-month follow up, however, the magnitude of toxicity changes with time. Few patients are willing to sacrifice medical care regardless of the cost. Risk factors for FT evolve, suggesting that different groups may benefit from financial intervention at diagnosis versus 6MFU.

Assessment of Financial Toxicity Among Patients With Advanced Lung Cancer in Western China

Financial toxicity of patients with lung cancer in China: Results from a National Survey Study

Financial Toxicity Assessment and Associated Factors Analysis of Patients with Cancer in China.

Influence of Financial Toxicity on the Quality of Life in Lung Cancer Patients Undergoing Immunotherapy: The Mediating Effect of Self-Perceived Burden

Influence of age on financial toxicity in cancer patients

Identifying the factors affecting financial toxicity status in patients with middle and advanced colorectal cancer: a cross-sectional study

Financial Toxicity in Female Patients with Breast Cancer: a National Cross-Sectional Study in China

The COmprehensive Score for financial Toxicity in China: Validation and Responsiveness

Assessment of the prevalence and related factors of financial toxicity in cancer patients based on the COST scale: A systematic review and meta-analysis

Health insurance as a moderator in the relationship between financial toxicity and medical cost‐coping behaviors: Evidence from patients with lung cancer in China

Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status?

Economic Burden for Lung Cancer Survivors in Urban China

The Evolution of Financial Toxicity in Patients with Lung Cancer.

Urban–rural differences in financial toxicity and its effect on cancer survivors’ health-related quality of life and emotional status: a latent class analysis

Factors influencing economic toxicity and coping strategies in lung cancer patients: A scoping review

Financial Toxicity of Cancer in China

Financial toxicity among older cancer survivors in China: a qualitative study of oncology providers' perceptions and practices

Determination of a cut-off COmprehensive Score for financial Toxicity (COST) for identifying cost-related treatment nonadherence and impaired health-related quality of life among Chinese patients with cancer

Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

Identifying a cut-off score for the COST measure to indicate high financial toxicity and low quality of life among cancer patients

Association of shared decision-making with financial toxicity and coping actions in adult patients with cancer: a nationwide study in China